- Home
- KULR vs NTHI Comparison
KULR vs NTHI Comparison
Compare KULR & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | NTHI |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 114.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | KULR | NTHI |
|---|---|---|
| Price | $2.62 | $3.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.4M | 65.4K |
| Earning Date | 05-15-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,274,028.00 | N/A |
| Revenue This Year | $123.93 | N/A |
| Revenue Next Year | $63.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.94 | $3.01 |
| 52 Week High | $6.30 | $12.99 |
Technical Indicators
Market Signals| Indicator | KULR | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 35.86 |
| Support Level | $2.05 | $3.01 |
| Resistance Level | $2.76 | $4.59 |
| Average True Range (ATR) | 0.24 | 0.38 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 10.60 | 25.55 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.